ARTORG Spin-Offs

Activities at the ARTORG Center span the arc from basic research enquiry into biomedical engineering domains to clinical introduction of novel technologies and procedures. Projects at the ARTORG are designed and pursued to achieve the goal of clinical translation. The ARTORG Center places great emphasis on supporting a sustainable pipeline of commercial venturing activities, from spin-offs to licensing and partnering. Learn more about our translational strategy here.

ARTORG Spin-offs:

  • Alexis Technologies AG, advanced lung-on-chip and tissue-modelling platforms
  • Alveolix AG, Organs-on-Chip for the preclinical market
  • AvaFlow GmbH, automated AI-based flow simulations for cardiovascular and cerebral haemodynamics
  • CASCINATION AG, Image-guided and robotic surgery for precision medicine applications
  • Crisalix SA, 3D/4D aesthetic-simulation software for plastic surgery
  • GoRehab AG, digital rehabilitation tools based on instrumented interfaces and data-driven motion-analysis algorithms
  • IMPLANZ AG, machine-learning and finite-element-based tools for diagonistic use in dental implantology
  • LEM Surgical, Next generation robotics
  • Neosoma GmbH, computational modelling and machine-learning for brain-tumour characterisation and treatment planning
  • Optimo Medical AG, patient-specific computational-biomechanics platform for cataract and refractive surgery
  • PeriVision SA, Helping Eye Doctors Save Vision with AI, VR and the cloud
  • RadVoyager GmbH, intelligent robotic and navigation solutions for interventional radiology
  • RetinAI / Ikerian AG, Deep learning for big data use in therapeutic decision making
  • SonoStent, The first non-invasively cleanable ureteral stent
  • SurgeonsLab AG, 4D simulation for microsurgical training and intervention planning
  • TightValve AG, surgical device to quantify aortic valve leakage intra-operatively
  • ValTech Lifesciences AG, next-generation prosthetic heart valves
  • Vitronco AG, vascularized tumor-on-chip services for oncology drug development
  • URODEA AG, The first non-invasive solution against urinary retention